Latest & greatest articles for migraine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on migraine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on migraine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for migraine

1. Acupuncture for migraine headaches

Acupuncture for migraine headaches Acupuncture for migraine headaches Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Acupuncture for migraine headaches View/ Open Date 2010-04 Format Metadata Abstract Acupuncture reduces the frequency of migraine headaches when used as an adjunct to, or in place of, medical management

2019 Clinical Inquiries

2. Acupuncture shows promise for preventing episodic migraines

Acupuncture shows promise for preventing episodic migraines Acupuncture shows promise for preventing episodic migraines Discover Portal Discover Portal Acupuncture shows promise for preventing episodic migraines Published on 18 October 2016 doi: Acupuncture was about as effective as long term medication in reducing the number of migraines. There were fewer adverse events amongst people receiving acupuncture (16-17%) compared to drug treatment (34%). Migraines affect around one in seven people (...) to people living in certain areas or who can afford to pay for treatment themselves. Share your views on the research. Why was this study needed? Migraines are common, affecting around one in five women and one in 15 men. Symptoms include headache, visual disturbances and nausea, which can be severe enough to stop people living their normal daily life. Migraine attacks last anywhere between four and 72 hours and are estimated to cost the UK economy as much as £2 billion a year in lost work. The cause

2019 NIHR Dissemination Centre

3. “Triptans” can relieve migraines in children and adolescents

“Triptans” can relieve migraines in children and adolescents “Triptans” can relieve migraines in children and adolescents Discover Portal Discover Portal “Triptans” can relieve migraines in children and adolescents Published on 13 September 2016 doi: Triptans, a migraine medication, relieve migraine headache completely within two hours compared to placebo. Ibuprofen was also effective but less well studied. This review was also reassuring in that any side effects of treatment were mild. Most (...) evidence identified in this Cochrane review was for sumatriptan, a commonly prescribed treatment for adults, compared to placebo or dummy pills. A few studies examined other triptans or other painkillers, such as ibuprofen or paracetamol against placebo in children and adults. The findings support current guideline recommendations to prescribe nasal triptans for migraine in adolescents. Only nasal preparations are currently licensed for adolescents, whereas oral administration and use for children

2019 NIHR Dissemination Centre

4. A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department

A Randomized Trial of a Long-Acting Depot Corticosteroid Versus Dexamethasone to Prevent Headache Recurrence Among Patients With Acute Migraine Who Are Discharged From an Emergency Department Migraine patients continue to report headache during the days and weeks after emergency department (ED) discharge. Dexamethasone is an evidence-based treatment of acute migraine that decreases the frequency of moderate or severe headache within 72 hours of ED discharge. We hypothesize that intramuscular (...) with moderate or severe migraine. Outcomes were assessed by telephone with a standardized instrument. The primary outcome was number of days with headache during the week after ED discharge. Secondary outcomes were complete freedom from headache, without the necessity of additional headache medication for the entire week after ED discharge, and medication preference, as determined by asking the patient whether he or she would want to receive the same medication again.One hundred nine patients received

2019 EvidenceUpdates

5. Erenumab (Aimovig) - for the prevention of migraine

Erenumab (Aimovig) - for the prevention of migraine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2019 Health Canada - Drug and Health Product Register

6. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study

Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study To evaluate the efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in the preventive treatment of chronic migraine.A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with chronic migraine (Evaluation of Galcanezumab in the Prevention of Chronic Migraine [REGAIN]) was a phase 3 study (...) with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Eligible patients 18 to 65 years of age with chronic migraine were randomized 2:1:1 to monthly subcutaneous injections of placebo (n = 558), galcanezumab 120 mg (with a 240-mg loading dose, n = 278), or galcanezumab 240 mg (n = 277). The primary endpoint was the overall mean change from baseline in the number of monthly migraine headache days (MHDs) during the 3-month double-blind treatment phase.Mean

Full Text available with Trip Pro

2018 EvidenceUpdates

7. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study

Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study To assess the efficacy and safety of lasmiditan in the acute treatment of migraine.Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours after dosing, patients used an electronic diary to record headache pain and the presence of nausea (...) , phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS).Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factors in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free of headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [OR] 2.6, 95% confidence interval [CI] 2.0-3.6, p< 0.001), similar to those dosed with lasmiditan 100 mg (28.2%; OR 2.2, 95% CI 1.6-3.0, p< 0.001). Furthermore

2018 EvidenceUpdates

8. Galcanezumab gnlm (Emgality) - For the preventive treatment of migraine in adults

Galcanezumab gnlm (Emgality) - For the preventive treatment of migraine in adults Drug Approval Package: Emgality (galcanezumab-gnlm) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Emgality (galcanezumab-gnlm) Company: Eli Lilly and Company Application Number: 761063 Approval Date: 09/27/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

2018 FDA - Drug Approval Package

9. Fremanezumab vfrm (Ajovy) - For the preventive treatment of migraine in adults

Fremanezumab vfrm (Ajovy) - For the preventive treatment of migraine in adults Drug Approval Package: Ajovy (fremanezumab-vfrm) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Ajovy (fremanezumab-vfrm) Company: Teva Pharmaceuticals USA, Inc. Application Number: 761089 Approval Date: 09/14/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF

2018 FDA - Drug Approval Package

10. Migraine headache in adults

Migraine headache in adults Migraine headache in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Migraine headache in adults Last reviewed: February 2019 Last updated: October 2018 Summary Migraine is a chronic, genetically determined, episodic, neurological disorder that usually presents in early-to-mid life. Patients complain of intermittent headache and associated symptoms, such as visual disturbance (...) , nausea, vomiting, and sensitivity to light or noise (photophobia and phonophobia). The diagnosis is based on history and physical examination. No laboratory or imaging tests are essential for diagnosis. Treatment approaches involve identification and avoidance of trigger factors, and the use of medication to treat the acute attack or prevent future attacks. There are no clinical trials that identify one migraine therapy (acute therapy or prophylaxis therapy) as superior over others. Triptans

2018 BMJ Best Practice

11. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. (PubMed)

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. A substantial proportion of patients with migraine does not respond to, or cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine. We assessed its efficacy and tolerability in patients with episodic migraine in whom (...) previous treatment with two-to-four migraine preventives had been unsuccessful.LIBERTY was a 12-week, double-blind, placebo-controlled randomised study at 59 sites in 16 countries. Eligible patients were aged 18-65 years and had a history of episodic migraine with or without aura for at least 12 months, had migraine for an average of 4-14 days per month during the 3 months before screening, and had been treated unsuccessfully (in terms of either efficacy or tolerability, or both) with between two

2018 Lancet

12. The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis

The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis – Morsels of Evidence \t\t\t\r\n\t\t\t \t\t\t\r\n\t\t\t Like this: Like Loading... ","author":{"@type":"Person","name":"Michael Tam"},"image":["https:\/\/evidencebasedmedicine.com.au\/wp-content\/uploads\/2018\/10\/cover.png"]} Toggle search form Toggle navigation Evidence-based medicine for general practitioners Oct 19 2018 (...) The combination of magnesium, riboflavin, and coenzyme Q10 for migraine prophylaxis By in , , Journal reference: Gaul C, Diener HC, Danesch U, Migravent Study G. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516. Link: Published: April 2015 Evidence cookie says… The evidence for combination magnesium, riboflavin, and CoQ10 is at best equivocal for migraine

Full Text available with Trip Pro

2018 Morsels of Evidence

13. Fremanezumab for preventive treatment of migraine: Functional status on headache-free days

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days To evaluate the effect of fremanezumab on the functional status on headache-free days in phase 2 episodic migraine (EM) and chronic migraine (CM) studies.Functional status data were collected prospectively via the electronic headache diary on all headache-free days by patients answering questions regarding work/school/household chore performance, speed of work completion, concentration, and feeling (...) . Further research is required to confirm these findings in a prospective study and to clarify the underlying mechanism(s).NCT02025556 and NCT02021773.This study provides Class II evidence that for patients with migraine, fremanezumab increases normal functional performance on headache-free days.Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Full Text available with Trip Pro

2018 EvidenceUpdates

14. Common migraine prevention treatments found to be equally effective

Common migraine prevention treatments found to be equally effective Common migraine prevention treatments found to be equally effective Discover Portal Discover Portal Common migraine prevention treatments found to be equally effective Published on 24 September 2015 doi: This review found that the main drugs used for preventing migraine were all effective compared with placebo or dummy treatment. The results were less clear cut when comparing drugs directly against each other as there were (...) fewer trials. This review highlights the range of drugs used to prevent migraines, reflecting the number of possible treatments available. The review’s conclusions suggest that the prescriber could be guided by individual patient characteristics, including preferences, pre-existing conditions and potential side effects. This review confirms and strengthens NICE guidance in this area. Share your views on the research. Why was this study needed? Migraines affect around 15% of people in the UK

2018 NIHR Dissemination Centre

15. Migraine and Tension Headache

Migraine and Tension Headache ? 2018 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Migraine and Tension Headache Guideline Background 2 Diagnosis Red flag warning signs 2 Differential diagnosis 2 Imaging 3 Migraine versus tension headache 3 Medication overuse headache 3 Menstruation-related migraine 3 Tension Headache Acute treatment 4 Prophylaxis 5 Migraine Headache Acute treatment 6 Treatment of refractory migraine 7 Prophylaxis 8 Menstruation-related migraine (...) Background This guideline includes diagnosis and treatment of the most common headache types that are managed in primary care: • Tension headache • Migraine headache, including menstrual migraine • Medication overuse headache (also known as rebound headache) Cluster headaches are excluded from this guideline because of their low prevalence in the general population and the severity of the symptoms. For patients with suspected cluster headaches, consider consulting with Neurology for evaluation

2018 Kaiser Permanente Clinical Guidelines

16. Erenumab (Aimovig) - Migraine

Erenumab (Aimovig) - Migraine 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 31 May 2018 EMA/CHMP/413393/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Aimovig International non-proprietary name: erenumab Procedure No. EMEA/H/C/004447/0000 Note Assessment report as adopted by the CHMP with all (...) Amgen Thousand Oaks BMI body mass index CDC complement dependent cytotoxicity CEX cation exchange CFU colony-forming unit cGMP current good manufacturing practices CGRP calcitonin gene-related peptide CHO chinese hamster ovary CI confidence interval CM chronic migraine CMH Cochran-Mantel-Haenszel CPP critical process parameter CPV continued process verification CQA critical quality attribute CSR clinical study report dFBS dialyzed fetal bovine serum DNA deoxyribonucleic acid DOE design

2018 European Medicines Agency - EPARs

17. Migraine

Migraine Top results for migraine - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for migraine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

18. Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value

Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Final Evidence Report July 3, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page ii Final Evidence Report – CGRP Inhibitors (...) for Episodic or Chronic Migraine ICER Staff and Consultants University of Illinois, Chicago Modeling Group Alexandra G. Ellis, PhD Senior Scientist, HTA and Economic Evaluation Institute for Clinical and Economic Review Ifeoma Otuonye, MPH Research Lead, Evidence Synthesis Institute for Clinical and Economic Review Varun Kumar, MBBS, MPH, MSc Health Economist Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical and Economic Review Matt Seidner

2018 California Technology Assessment Forum

19. Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study

Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for the acute treatment of migraine in a multicenter, double-blind, randomized, sham-controlled trial.A total of 248 participants with episodic migraine with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants (...) 1.2, 4.4; p = 0.012). nVNS demonstrated benefits across other endpoints including pain relief at 120 minutes and was safe and well-tolerated.This randomized sham-controlled trial supports the abortive efficacy of nVNS as early as 30 minutes and up to 60 minutes after an attack. Findings also suggest effective pain relief, tolerability, and practicality of nVNS for the acute treatment of episodic migraine.NCT02686034.This study provides Class I evidence that for patients with an episodic migraine

Full Text available with Trip Pro

2018 EvidenceUpdates

20. Migraine

Migraine Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history

2018 Trip Evidence Maps